Finasteride for benign prostatic hyperplasia (Q24234464)

1

0 references

Howard A Fink

2

0 references

Roderick MacDonald

3

0 references

Indy Rutks

Cochrane Database of Systematic Reviews

4

0 references

publication date

6 October 2010

0 references

published in

0 references

cites work

Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Comparison of tamsulosin and finasteride for lower urinary tract symptoms associated with benign prostatic hyperplasia in Korean patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Pharmacotherapy of benign prostatic hyperplasia: Inhibitor of 5 alpha-reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Stud

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Maximum Urinary Flow Rate by Uroflowmetry: Automatic or Visual Interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over the full range of baseline prostate sizes in men enrolled in the MTOPS trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Long-term effects of finasteride on prostate tissue composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Effects of finasteride and cyproterone acetate on hematuria associated with benign prostatic hyperplasia: a prospective, randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Finasteride Urodynamics Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Intra- and interobserver variability of MRI prostate volume measurements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

5-alpha-reductase inhibitors for lower urinary tract symptoms secondary to benign prostatic obstruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

Meta-analysis of the placebo response in antidepressant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Transition zone volume and transition zone ratio: predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Efficacy, tolerability, and effect on health-related quality of life of finasteride versus placebo in men with symptomatic benign prostatic hyperplasia: a community based study. CUSP Investigators. Community based study of Proscar

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

The effect of doxazosin, finasteride and combination therapy on nocturia in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Urodynamic Effects of Finasteride in the Treatment of Bladder Outlet Obstruction due to Benign Prostatic Hyperplasia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

The development of human benign prostatic hyperplasia with age

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Meta-Analysis of Randomized Clinical Trials of Finasteride

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Saw palmetto extract: newest (and oldest) treatment alternative for men with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Combined analysis of two multicenter studies of finasteride 5 mg in the treatment of symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

The effect of finasteride on prostate volume, urinary flow rate and symptom score in men with benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Five-year follow-up of patients with benign prostatic hyperplasia treated with finasteride.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

Finasteride for the treatment and control of benign prostatic hyperplasia: summary of phase III controlled studies. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1002/14651858.CD006015.PUB3

7 January 2021

10.1002/14651858.CD006015.PUB3

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3945009

OpenCitations bibliographic resource ID

3945009

1 reference